Equity Overview
Price & Market Data
Price: $6.71
Daily Change: -$0.40 / 5.96%
Range: $6.55 - $7.05
Market Cap: $24,340,862
Volume: 155,687
Performance Metrics
1 Week: -19.84%
1 Month: 0.92%
3 Months: -39.44%
6 Months: -42.61%
1 Year: -83.65%
YTD: -39.07%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.